Challenging Centeon's hold on the market for plasma protein therapies, Baxter International Inc. and Immuno International AG announced a worldwide strategic alliance that will unite Baxter's genetically engineered recombinant products with Immuno's plasma derivatives.

According to Baxter spokesperson Jill Carter, the alliance will focus on expansion of the global market for transfusion medical products that will include plasma derivatives (such as coagulation therapies, plasma expanders, immunoglobulins and immuno-based inhibitors), fibrin sealants used as adhesives for wound healing, and immunological vaccines.